1 **Digital health app data reveals an effect of ovarian hormones on long COVID and myalgic**

2 **encephalomyelitis symptoms**

4 **Authors:** Abigail Goodship MRes[1], Rory Preston MSc[2], Dr. Joseph T Hicks PhD[3], Harry Leeming

5 MEng [2], Christian Morgenstern MSci[3], Dr. Victoria Male PhD [1]

7   1.   Department of Metabolism, Digestion and Reproduction, Imperial College London, Chelsea

8   and Westminster Campus, London SW10 9NH

2.   Visible Health Inc., 251 Little Falls Dr., Wilmington DE, USA

3.   MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health,

Imperial College London, London, W12 7TA, UK

Corresponding author: Dr. Victoria Male PhD [1]
Telephone: 020 3315 800
Email: v.male@imperial.ac.uk
16

Summary

Background

Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) disproportionately

affect females, suggesting modulation by sex hormones. We sought to investigate whether symptom

severity is influenced by changes in sex hormones over the menstrual cycle, or by hormonal

contraception.

Methods

We carried out a retrospective analysis of menstrual and symptom data, prospectively collected via

the Visible app from individuals with long COVID, ME/CFS, or both, who had regular menstrual

cycles, between 7th September 2022 and 6th March 2024. Mixed-effects models were used to

examine associations between symptom severity, menstrual cycle phase and contraception type.

Findings

948 users were included; 100% of users were female and 92.6% identified as women. The most tracked

symptoms were fatigue (99·5% of users), brain fog (88·3%), headaches (85·1%) and muscle aches

(78·6%). All menstrual cycle phases showed a modest, but significant, improvement compared to the

menstrual phase, most markedly the early luteal (IRR = 0·963, 95% CI: 0·958–0·968), but also the

follicular (IRR = 0·985, 95% CI: 0·981–0·990) and late luteal phases (IRR = 0·980, 95% CI: 0·974–

0·985). Crashes (sudden and severe worsening of symptoms following exertion) were significantly more

frequent during menstruation than in other phases. Users of combined hormonal contraception (n=70)

had a statistically significant reduction in overall symptom score (OR = 0·827, 95% CI: 0·690–0·992)

and crash incidence (OR = 0·548, 95% CI: 0·350–0·856) compared to those not using contraception

(n=786).

Interpretation

Menstruation is associated with worsened symptoms in long COVID and ME/CFS. Users of combined

hormonal contraception report a lower symptom burden than non-users, suggesting a modulatory role

of ovarian hormones. These findings could empower menstruating people living with long COVID and

ME/CFS to anticipate cyclical changes in symptoms and plan their activities accordingly, and could

also inform their use of contraception.

Funding

UK Medical Research Council, NIHR, Community Jameel, the Eric and Wendy Schmidt Fund for

Strategic Innovation, Bill & Melinda Gates Foundation, Borne, Action Medical Research, and Genesis

Research Trust.

Introduction

Four years after the first identification of novel coronavirus SARS-CoV-2, the spread of coronavirus disease 2019 (COVID-19) continues to profoundly impact people's lives. Whilst most SARS-CoV-2 infections resolve within 4 weeks, over 10% progress to a chronic multisystemic condition known as 'long COVID'.[1] The Winter COVID-19 Infection study, conducted between November 2023 and March 2024, estimated that 2 million people currently live with long COVID in the UK.[2] Of those who reported having long COVID, 71·1% reported having long COVID for over a year, 51·3% over 2 years and 30·6% over 3 years.[2] Long COVID symptoms are wide-ranging, but commonly include fatigue, brain fog, shortness of breath, insomnia and post-exertional malaise,[3] and can significantly reduce quality of life.[4]

A substantial fraction of long COVID cases also meet the diagnostic criteria for myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS).[5–8] Whilst not all cases of ME/CFS have an identifiable infectious trigger, many are preceded by a viral infection such as glandular fever,[9] or Ross River virus.[10] The prevalence of ME/CFS is estimated to be between 0.59% and 1.3%,[11–13] and around a quarter of people living with with ME/CFS are housebound.[14] Despite the profound impact ME/CFS can have on quality of life, research has been consistently underfunded.[15] Given the historic neglect of ME/CFS and the recent emergence of long COVID, as well as the complexity of both diseases, many questions about their pathophysiology remain unanswered.

Long COVID and ME/CFS both affect approximately twice as many females as males[16,17] and higher oestrogen may be beneficial in females with acute COVID-19.[18,19] Whilst the pathophysiology of long COVID and ME/CFS are still unclear, a dysregulated immune response may play a role, with the discovery of autoantibodies in long COVID patients supporting the suggestion that long COVID could be an autoimmune disease.[6,20] Sex hormones (oestrogen, progesterone and testosterone) modulate sex differences in immune function[21] and phases of the menstrual cycle correlate with symptoms of chronic, and particularly autoimmune, conditions,[22] summarised in **Figure 1**. Symptoms of rheumatoid arthritis, inflammatory bowel disease, lupus, multiple sclerosis and asthma all worsen at or shortly before menstruation.[22] Hormonal contraception alters the cyclical fluctuations in ovarian hormones across the menstrual cycle and has an association with altered disease susceptibility and severity,[22] with users experiencing improved symptoms of multiple sclerosis.[23]

Cross-sectional surveys have suggested that long COVID symptoms may also vary with the menstrual cycle,[3,24] but these approaches can be affected by recruitment and recall bias. Many individuals track both menstrual cycles and disease symptoms using apps, entering data in real-time as part of their healthcare routine. Data collected in this way are less likely to be affected by recruitment bias than other methods of data collection.[25] Visible is an app designed for people with chronic health conditions (such as long COVID and ME/CFS) to track aspects of their health including symptoms, biometric measurements and other factors such as menstruation.[26] In this study, we used data from the Visible app to test two hypotheses: 1) Long COVID and ME/CFS symptoms are worse during the menstrual and premenstrual phases, improving in the mid-luteal phase, and 2) stabilising ovarian hormone levels with hormonal contraception is associated with improved symptoms.

Research in context

Evidence before this study

In acute COVID-19, there is evidence to suggest that oestrogen may have a protective effect. A Swedish cohort study of post-menopausal women infected with SARS-CoV-2 (Sund *et al.,* 2022) found that women with high oestrogen had a lower risk of death compared to controls and women with low oestrogen had higher risk of death compared to controls. Furthermore, a population-based matched cohort study of UK women found that users of the combined hormonal contraceptive pill (n=295,689) had lower rates of COVID-19 and a reduction in hospital attendance (Costeira *et al.,* 2021). To our knowledge, the impact of the menstrual cycle on ME/CFS symptoms had yet to be investigated prior to this study and research into long COVID and the menstrual cycle to date has been limited. Arguably one of the most influential studies in the general field of long COVID is from Davis *et al.* 2021 who reported the results of a large international patient-led survey. In addition to characterising symptom prevalence, Davis *et al.,* found that a third of menstruating participants (n =1792) reported relapses of their long COVID symptoms immediately before or during their period. In a smaller UK survey (Newson *et al.,* 2021, n = 460), 62% of female respondents with long COVID reported that their symptoms of long COVID were worse on the days before their period. However, the participant demographics were not reported, so it is unclear whether this is a representative sample.

Added value of this study

This study is the first to describe changes to long COVID and ME/CFS symptoms across the menstrual cycle, using prospectively collected app data. Symptoms tended to be worse during the menstrual phase and less severe during the early luteal phase, in line with our hypothesis and with previous findings. This study is also the first to investigate the effect of hormonal contraception on symptoms of long COVID and ME/CFS. Use of combined hormonal contraception was associated with significantly ameliorated symptoms and a reduced risk of crashes.

Implications of all the available evidence

The finding that long COVID and ME/CFS symptoms follow a cyclical pattern over the menstrual cycle not only gives us new insights into the role of sex hormones in these diseases but could also empower menstruating patients to schedule more strenuous activities during phases of the cycle when they are likely to have milder symptoms, and be less vulnerable to crashes (sudden and severe worsening of symptoms following exertion). The finding that combined hormonal contraceptives as associated with reduced symptoms could also inform the use of contraception in people living with long COVID and ME/CFS.

Methods

Data source and collection

A retrospective analysis of symptom severity and menstrual cycle phase was conducted on prospectively collected data from users of the Visible app. [26] On registration, users enter their birth year, gender and whether they consider themselves to have long COVID, ME/CFS or another condition. After consenting to participate, users were asked to complete a survey on their use of hormonal contraception, pregnancy status, breastfeeding status, number of pregnancies, and number of births. Each day, users were prompted to self-report their commonly experienced symptoms on a 4-point Likert scale [None, Mild, Moderate, Severe] and whether they are currently experiencing a crash **(appendix, p23)**. The following definition was provided: "Crashes usually occur as a part of post-exertional symptom exacerbation and affect your ability to carry out your usual activities. They normally last a few days." Reports entered between 7th September 2022 to 8th March 2024 were collected.

Data cleaning and menstrual cycle phase coding

All data cleaning and subsequent analysis was conducted in RStudio version 2024.12.0+467. [27] Users who did not complete the survey questions, or who were breastfeeding, pregnant or outside the age range 18-45 were excluded. Under-18s were not included due to the additional ethical approval that would have needed to be obtained when analysing data from children; over 45s were excluded due to an increased likelihood of being perimenopausal. Any users who did not have either long COVID or ME/CFS, who did not track menstrual data or who did not report a single day where they were menstruating were also excluded. A menstrual cycle was counted from the first day of one menstrual period to the first day of the next. The first day of a period was assigned based on the International Federation of Gynecology and Obstetrics (FIGO) definition of a normal period[28] where the day fulfilled all the following criteria: users reports being on period; user did not report being on their period the previous 5 days; the following day and the day after the user either reported being on their period or did not make a report; user did not report being on their period 9 and 10 days after.

Menstrual cycles that contained >2 consecutive days of missing menstrual tracking data or were outside of the normal length of a cycle (24-38 days, as defined by FIGO[28]) were removed from the dataset. Exclusion of users and cycles is summarised in **Figure 1C-D**. For all remaining cycles, any missing menstrual tracking data was imputed ('on period' or 'not on period') so that menstrual cycle phases could be assigned. Data was imputed from the previous day with data, with the following exception: missing data on the 9th or 10th day of the cycle was imputed as 'not on period', assuming duration of menses does not exceed the normal 8 days. [28] The period end date was assigned where the day fulfilled all the following criteria: user assigned as being on their period; user assigned as being on their period at least the previous 2 days; user assigned as not being on their period the following day.

After defining the last day of the period, a menstrual cycle phase was assigned to each day, according to the decision tree outlined in **Figure 1E.** This follows the assumption that the follicular phase is variable, and the luteal phase consistently accounts for the final 14 days of each cycle.[29] The luteal

phase was further divided into the early luteal (14-8 days before the first day of period (D1), late luteal
(7-3 days before D1) and premenstrual phase (2 days before D1).

Once menstrual cycle phases had been assigned to each day of all included cycles, any symptom and
sleep tracking associated with that day were integrated into the dataset. Retrospective symptom
reporting (symptom reported >2 days after date) was removed to reduce the risk of recall bias.

Descriptive statistics and statistical testing

Overall study population characteristics are summarised in **Table 1.** For each user, for each date, the
scores of each tracked symptom (all on a scale of 0-4) were summed to give an overall symptom score
and provide a single, comprehensive measure of a user's overall health, reflecting the cumulative
burden of symptoms. Incorporating the total number of symptoms experienced in addition to severity of
symptoms is important, as for many individuals with long COVID, navigating the volume of symptoms
feels overwhelming and unmanageable.[30] Gravidity was assessed as a binary variable (nulligravid or
multigravid), and the Mann-Whitney U-Test was used to test the association between gravidity and
mean symptom score. Kruskal-Wallis tests were used to assess the association between mean
symptom score and disease type, contraception type, quarters post-joining and age category. Post-hoc
pairwise comparisons were conducted with Dunn's tests, and p-values were adjusted using the
Bonferroni method to control for Type 1 error. For menstrual cycle phase, the mean of all overall
symptom scores across all dates in each cycle phase was calculated for each individual. The Friedman
test was used to compare symptom score means across phases. Post-hoc pairwise comparisons were
performed using the Nemenyi test. For R package details see **appendix (p23).** For all variables
described above, the mean of the mean overall symptom scores is presented as scatter plots in **Figure
2**, with pairwise significant comparisons shown on the plot ($p < 0.05$). The percentage of days classified
as a crash was calculated out of the total days with data and displayed as a scatter plot with mean +/-
standard error of the mean (SEM).

Mixed-effects modelling

Two separate generalized linear mixed-effects models were used to evaluate the effect of relevant variables on different outcomes: overall symptom score and crash occurrence. First, a negative binomial regression mixed-effects model was used to investigate overall symptom score. Fixed effects included menstrual phase, age category, disease type, contraception type, nulligravidity, and time since joining. 'Individual' was considered a random effect, which is recommended in menstrual cycle research[31] to reliably estimate between-person differences in within-person changes across the cycle.[31–33] Second, to evaluate the effect of the same set of variables on crash occurrence, a logistic regression (binomial family with a logit link) mixed-effects model was used. Fixed effects included menstrual phase, disease type, contraception type, quarters post-joining, nulligravidity and age category. 'Individual' was considered a random effect, to account for within-subject variability. Details of both models can be found in **appendix (p24-25).**

Ethics

All app users were given the option to consent to the use of their anonymised data for this study by checking a box in the "Research" section of the Visible app. Ethical approval for this study was obtained from the Research Governance and Integrity Team (study number 277771) at Imperial College London.

Role of the funding source

The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

Figure 1: Overview of the study

(A) A schematic representation of the menstrual cycle illustrates relative changes in pituitary and ovarian hormones, follicle development, and endometrial lining. Correlated changes in disease severity and infections are shown in the top panel, red indicates disease symptoms worsen/susceptibility to infection increases and green indicates disease symptoms improve/response to infection improves. Created in Biorender.com.[34] (B) Screenshots from the Visible app illustrate how users track individual disease symptoms, menstruation and crashes. Data was collected from 7th September 2022 to 6th March 2024. (C) Flow diagram to illustrate the data cleaning process of users. Red boxes show exclusions of users, blue boxes show the number of users (n) after exclusions. (D) Flow diagram to illustrate the data cleaning process of cycles after (C). Yellow boxes show cycle exclusions, turquoise boxes show the number of cycles (n) after exclusions. (E) The decision tree for assigning menstrual cycle phase to each day.

Results

Of the 2678 users who consented for their data to be used in the study period (7th September 2022 – 6th March 2024), 948 remained after data cleaning (**Figure 1C-D, Table 1**). Just under half the cohort identified as having long COVID (45·5%), around a third as having ME/CFS (34·7%) and a fifth (19·8%) as having both long COVID and ME/CFS. Almost all users identified as women (92·6%) and as not disabled (99·6%). The majority of users were not on hormonal contraception (82·9%), and the remainder were split fairly evenly between oestrogen and progestin combined hormonal contraception (combined pill (7·0%) or patch (0·4%), hereafter called "combined hormonal contraception") and progestin-only contraceptives (intrauterine system (5·5%) or progestogen-only pill (2·3%) or contraceptive implant (1·9%)). Around two-thirds of users had never been pregnant (65·1%) or given birth (72·5%). The median user age was 37 (interquartile range = 10, distribution shown in **appendix (p3)**. There were no significant differences between the characteristics of study participants in each of the disease groups **appendix (p3)**.

Table 1. Demographics of study population

Variable	Subgroups	Count (n)	Percentage (%)
Disease type	Long COVID	431	45·5
	ME/CFS	329	34·7
	Long COVID and ME/CFS	188	19·8
Age category	<30 years old	179	18·9
	30-39 years old	400	42·2
	≥40 years old	369	38·9
Gender	Woman	878	92·6
	Non-binary	61	6·4
	Prefer not to say	6	0·6
	Prefer to self-describe	3	0·3
Disabled	No	944	99·6
	Yes	4	0·4
Contraception type	None	786	82·9
	Combined pill	66	7·0
	Intrauterine system	52	5·5
	Progestogen-only pill	22	2·3
	Contraceptive implant	18	1·9
	Patch	4	0·4
Number of times been pregnant	0	617	65·1
	1	87	9·2
	2	132	13·9
	3	112	11·8
Number of times given birth	0	687	72·5
	1	71	7·5
	2	135	14·2
	3	55	5·8

All variables are displayed as count (n) and percentage (%) of the total users (N = 948)

To determine how overall disease severity changed over the cycle and with demographic
characteristics, we examined the daily sum of all symptom ratings, the 'symptom score', with higher
scores indicating higher severity. For each individual, we calculated the mean symptom score across
all relevant days. The mean symptom score was lowest in the early luteal phase, significantly higher
in the follicular (p=0·0043) and late luteal phase (p= 0·0037) and still higher in the menstrual (p=1·5e-
08) and premenstrual phases (p= 4·6e-05) (**Figure 2B**). Mean symptom scores were highest in users
with both long COVID and ME/CFS and were lowest in users with long COVID alone (**Figure 2C**).
Mean symptom scores from users with different contraception types, time since joining, gravidity and
age categories did not significantly differ in this initial analysis (**Figure 2D-G**), although there was a
near significant difference (p=0.076) between users of no hormonal contraception compared to
combined hormonal contraception (p=0·076) (**Figure 2D**).

On multivariable mixed-effects regression modelling, as symptom score was positively skewed and
over-dispersed (**Figure 2A**), we used negative binomial regression and incorporated random
intercepts for each user. The association between menstrual cycle phase and symptom score
remained significant adjusting for contraception type, disease type, age category, gravidity and time
since joining the app (**Table 2**). Symptom scores were significantly higher during menstruation than in
all other cycle phases. Compared to the menstrual phase, the early luteal phase showed the greatest
reduction in symptom scores (incidence rate ratio (IRR)=0·963, p=5·77E-46); the follicular and late
luteal phases also showed significant reductions (IRR=0·985, p=6·49E-09 and IRR=0·980, p=4·96E-
13, respectively); and the smallest reduction was observed in the premenstrual phase (IRR=0·992,
p=0·0425). In the regression model, symptom scores were significantly lower in users of combined
hormonal contraception (IRR=0·872, p=0·041), in comparison to users not on hormonal
contraception. Users on progestin-only contraception also had lower symptom scores compared to
users not on hormonal contraception, but the difference was not significantly different (IRR=0·985,
p=0·848). In comparison to those with long COVID, users with ME/CFS had significantly higher
overall symptom scores (IRR=1·21, p=0·000408), and users with both long COVID and ME/CFS had
even higher overall symptom scores (IRR=1·52, p=6·11E-11). Compared to reports submitted in the
first three months since joining the app, symptom scores significantly increased over time, and by the
fifth quarter IRR = 1·06, p =7·8E-49. This was associated with an increase in the number of
symptoms tracked over time **(appendix, p4).** Age and gravidity did not show a significant association
with symptom scores.
305

306
307
308
309

310
Figure 2: The effects of menstrual phase, disease type, contraception type, time, gravidity and
age on mean symptom severity
(A) Distribution of mean symptom scores is shown as a histogram, binwidth = 0·5. (B-G) Mean
symptom score was calculated by first summing the scores of each tracked symptom (all on a scale of
0-4) and secondly taking the mean across all days for each individual. Scatter plots show mean
symptom score split by menstrual phase (B), disease type (C), contraception type (D), quarters post-
joining (E), gravidity (F) and age category (G). Mean symptom score is displayed as mean +/- SEM.
The Friedman test plus Nemenyi pairwise comparisons was used to test the significance between
mean symptom score and menstrual phase, due to the repeated measures nature of the data. The
Mann-Whitney U-Test was used to test the significance between gravidity and mean symptom score,

due to the binary nature of the variable. Unpaired Kruskal-Wallis tests was used to test significance for all other variables, Dunn's test was used for post-hoc comparisons and p values were adjusted using the Bonferroni method. P > 0.05 are considered not significant, P ≤ 0·05 are given 1 asterisk (*), P ≤ 0·01 are given 2 asterisks (**), P ≤ 0·001 are given 3 asterisks (***), P ≤ 0·0001 are given 4 asterisks (****). (H) Scatter plot showing mean percentage of days classified as a crash, displayed as mean +/- SEM.

Table 2. The fitting result of negative binomial regression model (overall symptom score)

Fixed effects	Incidence rate ratio	95% confidence interval (CI) (lower)	95% CI (upper)	P value
Menstrual phase				
Menses	-	-	-	-
Follicular	0·985	0·981	0·990	6·49E-09*
Early luteal	0·963	0·958	0·968	5·77E-46*
Late luteal	0·980	0·974	0·985	4·96E-13*
Premenstrual	0·992	0·985	1·00	0·0425*
Hormonal contraception type				
None	-	-	-	-
Oestrogen & progestin	0·827	0·690	0·992	0·041*
Progestin only	0·985	0·839	1·15	0·848
Disease type				
Long COVID only	-	-	-	-
ME/CFS only	1·21	1·09	1·35	0·000408*
Long COVID and ME/CFS	1·52	1·34	1·73	6·11E-11*
Age category				
< 30	-	-	-	-
30-39	0·982	0·860	1·12	0·790
>= 40	0·913	0·789	1·06	0·223
Gravidity				
Multigravida	-	-	-	-
Nulligravida	0·911	0·815	1·02	0·0992
Quarters post-joining				
1	-	-	-	-
2	1·01	1·00	1·01	0·00207*
3	1·01	1·00	1·02	0·000786*
4	1·04	1·03	1·05	1·13E-29*
5	1·06	1·05	1·06	7·8E-49*
6	1·05	1·03	1·07	4·32E-05*

* P value <0·05
Random effect: Individual (intercept) Variance: 0·5421 Standard deviation: 0·7363

The most tracked symptoms across all users were fatigue (99·5%), brain fog (88·3%), headaches (85·1%) and muscle aches (78·6%) **(appendix, p4)**. These symptoms were frequently co-reported with each other and with the following symptoms: dizziness, nausea, muscle weakness, joint pain, shortness of breath, palpitations, light sensitivity, noise sensitivity and memory issues **(appendix, p5-6)**. Restricting the analysis to the first three cycles enabled us to conduct Pearson's chi-squared tests as there were equal numbers of cycles for each user, and in this analysis, 25/36 individual symptoms differed significantly between menstrual cycle phases **(appendix, p7-9)**. However, this approach may overlook long-term trends and variations in symptoms over time so we also built individual regression models for each symptom **(appendix, p10-21)**. In this analysis 32/36 symptoms showed a significant association between symptom severity and menstrual cycle phase, with 22 of these being worse in the menstrual phase and better in the luteal phase **(appendix, p10-21).**

Approximately 85% of those affected by long COVID experience episodic symptoms that can rapidly fluctuate from periods of symptom stability to severe exacerbations, resulting in significant functional declines.[3] These periods of severe worsening symptoms are often called "crashes" by those living with complex chronic illnesses,[35] who may choose, where possible, to avoid scheduling strenuous activities at times when they are more vulnerable to a crash. The frequency of crashes was higher during menses, compared to all other phases, particularly the early luteal phase (p = 0·0002680) **(appendix, p22)**. The mean percentage of days with crash was highest in the menstrual phase and decreased over the cycle, plateauing between the early luteal and premenstrual phases (**Figure 2H**). Adjusting for contraception type, disease type, age category, gravidity and time since joining the app using a mixed-effects logistic regression model, crashes remained less frequent in every phase compared to menstruation (**Table 3**). The late luteal phase showed the greatest reduction in crashes (odds ratio (OR)=0·888, p=5·87E-05) compared to the menstrual phase. The follicular, early luteal and premenstrual phase also showed significant reductions (OR=0·947, p=0·0367 and OR=0·900, p=0·000109 and OR=0·919, p=0·0333, respectively).

Crashes were significantly less frequent in users on combined hormonal contraception (OR=0·548, p=0·0409), compared to users not on hormonal contraception. Users on progestin-only contraception also had fewer crashes compared to users not on hormonal contraception but this was not significantly different (OR=0·864, p=0·446). In comparison to those with long COVID, users with ME/CFS had significantly more crashes (OR=1·47, p=0·00291) and users with both long COVID and ME/CFS had higher odds of crash (OR=1·85, p=4·4E-05). Age and gravidity were not significantly associated with crashes.

Table 3. The fitting result of binomial regression model (crashes)

Fixed effects	Odds ratio (OR)	95% CI (lower)	95% CI (upper)	P value
Menstrual phase				
Menses	-	-	-	-
Follicular	0·947	0·900	0·997	0·0367*
Early luteal	0·900	0·853	0·949	0·000109*
Late luteal	0·888	0·838	0·941	5·87E-05*
Premenstrual	0·919	0·851	0·993	0·0333*
Hormonal contraception type				
None	-	-	-	-
Oestrogen & progestin	0·548	0·350	0·856	0·00822*
Progestin only	0·864	0·593	1·260	0·446
Disease type				
Long COVID only	-	-	-	-
ME/CFS only	1·47	1·14	1·89	0·00291*
Long COVID and ME/CFS	1·85	1·38	2·48	4·4E-05*
Age category				
< 30	-	-	-	-
30-39	0·752	0·549	1·03	0·0761
>= 40	0·799	0·564	1·13	0·209
Gravidity				
Multigravida	-	-	-	-
Nulligravida	1·00	0·768	1·30	0·998
Quarters post-joining				
1	-	-	-	-
2	0·943	0·894	0·994	0·0304*
3	0·937	0·881	0·997	0·0396*
4	1·10	1·02	1·18	0·00916*
5	0·979	0·903	1·06	0·598
6	1·09	0·851	1·40	0·495

* P value <0·05
Random effect: Individual (intercept) Variance: 0·5414 Standard deviation: 0·7358

Discussion

This study is the first to describe changes to long COVID and ME/CFS symptoms across the menstrual cycle, using prospectively collected app data. In line with previous reports, overall symptom scores and crash incidence varied by disease, with the lowest scores reported in individuals with long COVID, higher scores in individuals with ME/CFS and the highest scores in individuals with both.[7] The most tracked symptoms and clustering are broadly in line with Davis *et al.* 2021 who found that fatigue and brain fog were the most frequent symptoms in long COVID patients after 6 months of the study, alongside post-exertional malaise/crashes[3].

When daily symptom ratings were summed to form an overall symptom score, there were small but significant changes between phases: symptoms were most severe in the menstrual and premenstrual phases and least severe in the early luteal phase. We saw a similar pattern with crash incidence, and these findings are in line with our hypothesis and with previous findings [3,17]. When disease type, age, reproductive history and contraception type were adjusted for, the menstrual cycle phase still had a small, but significant impact on symptom score and crashes. Use of combined hormonal contraception was associated with significantly ameliorated symptoms and a reduced risk of crashes. This warrants further investigation as combined hormonal contraception is generally considered safe, cheap and is already widely available – making it a promising approach to ameliorate long COVID and ME/CFS symptoms.

The major strength of this study is its use of data prospectively collected from a large cohort of users of the Visible app. Users enter data in real time as part of their personal healthcare routines, reducing recall and recruitment bias. The availability of a large volume of data enabled us to examine changes over the menstrual cycle in granular detail, since sufficient user-days were assigned to even the shortest phase (premenstrual) for statistical analysis. The comprehensive list of 36 symptoms tracked allows a thorough investigation into the effect of menstrual cycle phase on long COVID and ME/CFS. The use of 4-point Likert scales for symptom severity ensured consistency in data reporting and analysis. This approach also allowed us to calculate an 'overall symptom score' as a single comprehensive indicator of a user's health on any given day. We also examined individual symptoms and crashes to provide a more detailed picture of symptom severity.

The use of app data also carries some limitations. Our data is a convenience sample. Individuals with limited access to technology or digital literacy are unlikely to be app users, and individuals who choose to use the app and participate in the study might also have different characteristics or health behaviours compared to those who do not, potentially limiting the applicability of the results. Importantly, our study also relies on self-reported disease status, which may introduce inaccuracies into disease group assignments, and daily symptoms, which may introduce biases such as over-reporting or under-reporting of symptoms, and inaccuracies in tracking. Different users might also interpret and rate symptoms differently. However, to address this issue, we included 'individual' as a random effect in the model. The userbase of the app also means that there are no healthy controls, which prevents us from determining whether changes in long COVID and ME/CFS symptoms are due to the ovarian hormones

affecting the disease, or whether the observed change in symptoms reflects normal variation in
wellbeing across the menstrual cycle. However, our finding that combined hormonal contraception is
associated with lower symptom scores, does support the hypothesis that ovarian hormones directly
affect disease symptoms.

While our model adjusts for several variables, there may still be unmeasured confounders. Within-
individual analysis means that the association between symptom severity and menstrual cycle phase
is likely to be robust to this, but this could certainly affect the relationship between contraceptive use
and symptoms. Furthermore, the demographic survey questions were completed when the user first
enrolled and were not updated over the study. Therefore, any changes in contraception use during the
study would not have been captured. To minimise the cognitive burden of participation on app users,
we designed the survey to be as short as possible, but this meant we did not collect information on
other geographic location, ethnicity, socioeconomic status, body-mass index, education or other health
conditions including gynaecological disorders. Nor were we able capture daily contraception
information, including emergency contraception use, or any other hormonal intake (e.g. testosterone or
hormone replacement therapy (HRT)).

The results presented here support the idea that menstrual cycle phase influences long COVID and
ME/CFS symptoms. Broadly, people living with long COVID or ME/CFS may notice that their symptoms
are worse during the perimenstrual period and better in the early luteal phase. The knowledge that they
are more likely to crash during menstruation could improve quality of life, by allowing them to schedule
strenuous activities, which might cause a crash and cannot be carried out during a crash, for other
phases of the menstrual cycle. Furthermore, the association between combined hormonal
contraceptives, lower symptom scores and fewer crashes points towards a role for ovarian hormones
in modulating symptoms and highlights the therapeutic potential of oestrogen-containing contraceptives
in long COVID and ME/CFS.

Declarations

Funding AG is funded by the UK Medical Research Council (MRC) [grant number MR/W00710X/1]. CM acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (MR/X020258/1), the NIHR (NIHR200908); a philanthropic donation from Community Jameel supporting the work of the Jameel Institute; The Eric and Wendy Schmidt Fund (G-22-63345). JTH acknowledges funding from the Bill & Melinda Gates Foundation (INV-005289). VM acknowledges funding from Borne, Action Medical Research (GN2971), the UK Medical Research Council (MR/X006875/1) and Genesis Research Trust. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. For the purpose of open access, the author has applied a 'Creative Commons Attribution' (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Availability of data and materials While all data used in this analysis were anonymised, the individual-level nature of the data used risks individuals being identified or being able to self-identify if it is released publicly. However, the app data can be requested by bona fide researchers for specified scientific purposes by emailing info@makevisible.com.

Code availability

https://github.com/AbiGoodship/effect_of_ovarian_hormones_on_long_COVID_and_ME_symptoms

Competing interests. During the course of the study HL was employed by, and RP was a paid contractor for Visible Health Inc., the company that owns and operates the Visible app. Some of the study participants had paid for access to certain Visible features, though not access to symptom tracking or menstrual cycle tracking functionality which is free for all Visible app users. This was a study across both the free and paid user base. All other authors declare no competing interests.

Authors' Contributions VM and CM conceptualised the study. RP and HL curated the data. JH, AG and CM developed the methodology. AG formally analysed and visualised the data. CM and VM supervised the study. AG wrote the original manuscript draft. All authors were responsible for the methodology and review and editing of the manuscript. All authors discussed, edited, and approved the final version of the manuscript. All authors had final responsibility for the decision to submit the manuscript for publication.

References

Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; **21**. DOI:10.1038/s41579-022-00846-2.

Self-reported coronavirus (COVID-19) infections and associated symptoms, England and Scotland - Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/selfreportedcoronaviruscovid19infectionsandassociatedsymptomsenglandandscotland/november2023tomarch2024#long-covid (accessed July 22, 2024).

Davis HE, Assaf GS, McCorkell L, *et al.* Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine* 2021; **38**. DOI:10.1016/j.eclinm.2021.101019.

Carlile O, Briggs A, Henderson AD, *et al.* Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT). *The Lancet Regional Health - Europe* 2024; **40**: 100908.

Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-A systemic review and comparison of clinical presentation and symptomatology. *Medicina (Lithuania)* 2021; **57**. DOI:10.3390/medicina57050418.

Sukocheva OA, Maksoud R, Beeraka NM, *et al.* Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. J Adv Res. 2022; **40**. DOI:10.1016/j.jare.2021.11.013.

Haider S, Janowski AJ, Lesnak JB, *et al.* A comparison of pain, fatigue, and function between post-COVID-19 condition, fibromyalgia, and chronic fatigue syndrome: a survey study. *Pain* 2023; **164**: 385–401.

Kedor C, Freitag H, Meyer-Arndt L, *et al.* A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. *Nature Communications 2022 13:1* 2022; **13**: 1–13.

Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic Fatigue Syndrome After Infectious Mononucleosis in Adolescents. *Pediatrics* 2009; **124**: 189–93.

Hickie I, Davenport T, Wakefield D, *et al.* Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. *BMJ* 2006; **333**: 575.

Valdez AR, Hancock EE, Adebayo S, *et al.* Estimating prevalence, demographics, and costs of ME/CFS using large scale medical claims data and machine learning. *Front Pediatr* 2019; **6**: 433309.

Vahratian A, Lin J-MS, Bertolli J, Unger ER. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021-2022. 2023; published online Dec 13. DOI:10.15620/CDC:134504.

Samms GL, Ponting CP. Unequal access to diagnosis of myalgic encephalomyelitis in England. *medRxiv* 2024; : 2024.01.31.24302070.

Pendergrast T, Brown A, Sunnquist M, *et al.* Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome. *Chronic Illn* 2016; **12**: 292–307.

Smith K. Women's health research lacks funding — these charts show how. *Nature* 2023; **617**. DOI:10.1038/d41586-023-01475-2.

Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *J Transl Med* 2020; **18**. DOI:10.1186/S12967-020-02269-0.

Sigfrid L, Drake TM, Pauley E, *et al.* Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. *The Lancet Regional Health - Europe* 2021; **8**. DOI:10.1016/j.lanepe.2021.100186.

Sund M, Fonseca-Rodríguez O, Josefsson A, Welen K, Fors Connolly AM. Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: A cohort study. *BMJ Open* 2022; **12**. DOI:10.1136/bmjopen-2021-053032.

Costeira R, Lee KA, Murray B, *et al.* Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study. *PLoS One* 2021; **16**. DOI:10.1371/journal.pone.0257051.

Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023; **23**. DOI:10.1038/s41577-023-00904-7.

Hoffmann JP, Liu JA, Seddu K, Klein SL. Sex hormone signaling and regulation of immune function. Immunity. 2023; **56**. DOI:10.1016/j.immuni.2023.10.008.

22　Alvergne A, Högqvist Tabor V. Is Female Health Cyclical? Evolutionary Perspectives on
Menstruation. Trends Ecol Evol. 2018; **33**. DOI:10.1016/j.tree.2018.03.006.
23　Kempe P, Hammar M, Brynhildsen J. Symptoms of multiple sclerosis during use of combined
hormonal contraception. *European Journal of Obstetrics and Gynecology and Reproductive*
Biology 2015; **193**. DOI:10.1016/j.ejogrb.2015.06.030.
24　Newson L, Lewis R, O'Hara M. Long Covid and menopause - the important role of hormones
in Long Covid must be considered. *Maturitas* 2021; **152**. DOI:10.1016/j.maturitas.2021.08.026.
25　Milne-Ives M, Van Velthoven MH, Meinert E. Mobile apps for real-world evidence in health
care. Journal of the American Medical Informatics Association. 2020; **27**.
DOI:10.1093/jamia/ocaa036.
26　Visible - Activity tracking for Long Covid and ME/CFS. https://www.makevisible.com/
(accessed Aug 2, 2024).
27　Posit team. RStudio: Integrated Development Environment for R. 2024.
28　Munro MG, Critchley HOD, Fraser IS, *et al.* The two FIGO systems for normal and abnormal
uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the
reproductive years: 2018 revisions. *International Journal of Gynecology and Obstetrics* 2018;
143. DOI:10.1002/ijgo.12666.
29　Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. 2000.
30　Wurz A, Culos-Reed SN, Franklin K, DeMars J, Wrightson JG, Twomey R. 'I feel like my body
is broken': exploring the experiences of people living with long COVID. *Quality of Life*
Research 2022; **31**. DOI:10.1007/s11136-022-03176-1.
31　Schmalenberger KM, Tauseef HA, Barone JC, *et al.* How to study the menstrual cycle:
Practical tools and recommendations. Psychoneuroendocrinology. 2021; **123**.
DOI:10.1016/j.psyneuen.2020.104895.
32　Wei SM, Schiller CE, Schmidt PJ, Rubinow DR. The role of ovarian steroids in affective
disorders. Curr Opin Behav Sci. 2018; **23**. DOI:10.1016/j.cobeha.2018.04.013.
33　Gehlert S, Song IH, Chang CH, Hartlage SA. The prevalence of premenstrual dysphoric
disorder in a randomly selected group of urban and rural women. *Psychol Med* 2009; **39**.
DOI:10.1017/S003329170800322X.
34　Scientific Image and Illustration Software | BioRender. https://www.biorender.com/ (accessed
Aug 8, 2024).
35　O'Brien KK, Brown DA, McDuff K, *et al.* Conceptualising the episodic nature of disability
among adults living with Long COVID: a qualitative study. *BMJ Glob Health* 2023; **8**.
DOI:10.1136/BMJGH-2022-011276.
556